ArticleFrontiers in pharmacology2025
Analyzing antibacterial potential of bellamya
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prosthetic Joint Infection (PJI) is a serious and potentially fatal consequence of total joint arthroplasty that is primarily due to the formation of bacterial biofilms on surgical orthopedic implants. Such orthopedic infections often face antibiotic resistance; therefore, novel antimicrobial substances are in demand to combat the biofilm-associated infections in orthopedic implants. This study investigated the potential of AgNPs-AMP conjugate coated implants in combating micro-organisms responsible for biofilm formation on orthopedic joint implants causing PJI. Methods: Green synthesized AgNPs from leaf extracts were conjugated with the AMP extracted from the Bellamya bengalensis, which was characterized using UV Spectroscopy, zeta potential. The antibacterial activity of the AgNPs, AMP and AgNPs-AMP conjugate were assessed using the Well diffusion method. The effect of biofilm formation and inhibition of Staphylococcus aureus, and Staphylococcus epidermidis on the ½ MIC, 1X MIC, and 2X MIC were investigated using agar diffusion test. In addition, MTT assay was performed to determine the cytotoxic effects of AMP-AgNPs conjugate on the L929 cell line. Results: The UV Vis spectroscopy and zeta potential confirmed the synthesis of AgNPs, as well as the conjugation of AMP with AgNPs. The AMP-AgNPs revealed their significant bactericidal potential against the S. aureus, and S. epidermidis, with the antibacterial testing. The quantitative and qualitative analysis of biofilm inhibition revealed that all the tested concentrations of AMP-AgNPs conjugate (½ MIC, 1X MIC, and 2X MIC) effectively inhibited the biofilm formation of S. aureus and S. epidermidis. Discussion: It was concluded that the treatment of different concentrations of AMP-AgNPs did not influence the cell viability of the L929 cells. This study demonstrated that the AgNPs-AMP can be coated with orthopedic implants to prevent biofilm formation on orthopedic joint implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.